109 related articles for article (PubMed ID: 12910674)
1. [Plasma haemostatic and fibrinolytic activities and their relationship to levels of serum lipids and apolipoproteins in endogenous hypertriglyceridemic patients].
Shen T; Bai H; Liu B; Liu Y; Zhang Z; Deng Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):405-8. PubMed ID: 12910674
[TBL] [Abstract][Full Text] [Related]
2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
3. [Effects of hypertriglyceridemia on platelet activities in endogenous hypertriglyceridemic patients].
Shen T; Liu BW; Liu Y; Bai H; Zhang ZH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):15-7. PubMed ID: 14981803
[TBL] [Abstract][Full Text] [Related]
4. Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system.
Hiraga T; Shimada M; Tsukada T; Murase T
Horm Metab Res; 1996 Nov; 28(11):603-6. PubMed ID: 8960902
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
7. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
Crutchley DJ; McPhee GV; Terris MF; Canossa-Terris MA
Arteriosclerosis; 1989; 9(6):934-9. PubMed ID: 2511826
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
9. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
11. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
[TBL] [Abstract][Full Text] [Related]
12. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
14. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A; Bruni F
Int J Clin Pharmacol Res; 2001; 21(3-4):147-55. PubMed ID: 12067144
[TBL] [Abstract][Full Text] [Related]
15. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
16. Relation of habitual diet and cardiorespiratory fitness to blood coagulation and fibrinolytic factors.
Rankinen T; Rauramaa R; Väisänen S; Penttilä IM; Uusitupa M
Thromb Haemost; 1994 Feb; 71(2):180-3. PubMed ID: 8191395
[TBL] [Abstract][Full Text] [Related]
17. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
18. Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E.
Brouwers MC; Govers-Riemslag J; Schalkwijk CG; van Greevenbroek MM; van der Kallen CJ; Bekers O; van Dieijen-Visser MP; Ten Oever J; Bilderbeek-Beckers MA; de Bruin TW; Ten Cate H; Stehouwer CD
Thromb Res; 2008; 122(4):466-72. PubMed ID: 18262228
[TBL] [Abstract][Full Text] [Related]
19. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
20. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]